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Background: Previous studies showed that radiolabeled murine monoclonal antibody (mAb) 14C5 and its Fab and
F(ab')2 fragments, targeting αvβ5 integrin, have promising properties for diagnostic and therapeutic applications in
cancer. To diminish the risk of generating a human anti-mouse antibody response in patients, chimeric variants
were created. The purpose of this study was to recombinantly produce chimeric antibody (chAb) derivatives of the
murine mAb 14C5 and to evaluate the in vitro and in vivo characteristics.
Methods: In vitro stability, specificity, and affinity of radioiodinated chAb and fragments (Iodo-Gen method) were
examined on high-expressing αvβ5 A549 lung tumor cells. In vivo biodistribution and pharmacokinetic
characteristics were studied in A549 lung tumor-bearing Swiss Nu/Nu mice.
Results: Saturation binding experiments revealed high in vitro affinity of radioiodinated chAb, F(ab')2, and Fab, with
dissociation constants (KD) of 1.19 ± 0.19, 0.68 ± 0.10, and 2.11 ± 0.58 nM, respectively. ChAb 14C5 showed highest
tumor uptake (approximately 10%ID/g) at 24 h post injection, corresponding with other high-affinity Abs. ChF(ab')2
and chFab fragments showed faster clearance from the blood compared to the intact Ab.
Conclusions: The chimerization of mAb 14C5 and its fragments has no or negligible effect on the properties of the
antibody. In vitro and in vivo properties show that the chAb 14C5 is promising for radioimmunotherapy, due to its
high maximum tumor uptake and its long retention in the tumor. The chF(ab')2 fragment shows a similar receptor
affinity and a faster blood clearance, causing less non-specific retention than the chAb. Due to their fast blood
clearance, the fragments show high potential for radioimmunodiagnosis.
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Tumorigenesis and cancer progression are multi-step
processes. During cancer progression the ability to
invade and metastasize is a very important aggravating
factor. Modulation of crosstalk between cells and/or cell
extracellular matrix (ECM) adhesive components is of key
importance for the occurrence of metastasis [1]. This
modulation includes the release of proteases that remodel
the ECM, the deposition of new ECM molecules, and* Correspondence: Caroline.Dumolyn@UGent.be
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such as integrins. Integrins are a family of transmembrane
heterodimer glycoprotein cell surface receptors primarily
responsible for exchanging information between cells and
the surface surrounding ECM. Overexpression of certain
integrins on tumor cells, tumor stroma, or neovasculature
makes these receptors attractive targets for specific cancer
therapy. Two interesting targets in this context are the
vascular integrins αvβ3 and αvβ5 for which it is still unclear
if they promote [2] or inhibit [3] neovascularization. How-
ever, antibodies targeting these molecules can inhibit
neovasculature formation, making anti-αvβ3 and anti-αvβ5
antibody-based immunotherapy a viable option [4,5].
Abegrin™, for example, is a humanized monoclonal anti-is an Open Access article distributed under the terms of the Creative Commons
g/licenses/by/2.0), which permits unrestricted use, distribution, and reproduction
roperly cited.
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tumor growth-inhibiting, and anti-bone metastatic capaci-
ties [6-10]. The murine mAb 14C5 binds the integrin
αvβ5, a close relative of αvβ3. In vitro and in vivo studies
showed the radioiodinated murine mAb 14C5 to have
promising properties for diagnostic and therapeutic appli-
cations against integrin αvβ5-expressing tumor cells and/
or tumor surrounding stromal cells, for example, fibro-
blasts [11-14].
Full-sized Abs need to overcome some obstacles be-
fore penetrating into a tumor. Although big molecules
are able to extravasate out of the ‘leaky vessels’ near the
tumor, penetration of Abs into the tumor can still be
hampered by some physiological barriers, such as high
interstitial pressure and a ‘binding site barrier’ [15,16].
In order to improve the penetration within tumor
masses, fragments of mAb 14C5 have been created and
evaluated. In vitro and in vivo studies demonstrated the
efficient tumor targeting properties of murine 131I-Fab
and 131I-F(ab')2 14C5 fragments [17]. Despite the prom-
ising pre-clinical results, the clinical application of Ab
14C5 and its derivatives could be hampered due to its
murine origin. The development of a human anti-mouse
Ab (HAMA) response can result in tachyphylaxis, i.e.,
reduced therapeutic effect caused by reduced targeting
of the murine Ab due to immune complex formation
after repetitive administration of the Ab. More severe,
but rare, side effects of a HAMA response can range
from hypersensitivity to life-threatening anaphylactic
reactions [18,19]. In order to diminish the risk of
generating a HAMA response after Ab-based therapy
and thus avoid the associated disadvantages, the murine
Ab sequence is made to better resemble human Abs.
Chimerization is the first major step towards a humanized
molecule and includes the substitution of the mouse heavy
and light constant regions with human Ab counterparts
[20,21].
In the current study, the mAb 14C5 was chimerized to
reduce the risk of HAMA responses in patients. Due to
alterations in the chimeric (ch) Ab sequences, confor-
mational changes, changes in affinity, and/or alterations
of in vivo characteristics can occur as compared to the
established characteristics of the murine variant. There-
fore, the in vitro and in vivo targeting properties of the
chAb and its fragments were investigated to confirm
their αvβ5 targeting properties in vitro and in vivo.
Methods
Cells
HEK293T, a human embryonic kidney cell line trans-
fected with the SV40 large T-Ag (SV40TtsA1609) [22],
was used for transient eukaryotic expression. A549 is a
αvβ5
+ non-small cell lung cancer cell line [13]. Both cell
lines were grown in DMEM containing 10% fetal bovineserum (FBS) (Lonza, Verviers, Belgium). Colo16 is a αvβ5
−
squamous cell carcinoma cell line [13] grown in RPMI
1640 medium supplemented with 10% FBS. All cells were
cultured in an incubator at 37°C with 5% CO2.
Expression plasmids
The pES31Hneo and pES33Ezeo expression plasmids have
been described previously [23]. Restriction enzymes were
purchased from Fermentas (St. Leon-Rot, Germany),
primers (see Additional file 1) from Invitrogen (Life Tech-
nologies, Merelbeke, Belgium), and DNA-modifying en-
zymes and Vent-DNA polymerase from Biolabs (Beverly,
MA, USA). All vector constructs were sequence-verified
after cloning. The 14C5 VH region was amplified from
the murine 14C5 heavy chain [24] by polymerase chain
reaction (PCR) with primers 14C5 VH B SOE and NM
101F, and the PH1 CH1 was amplified from the IgG1 PH1
human Ab heavy chain [23] with PH1 CH1 F SOE and
NM 263 B. After splice overlap extension (SOE) PCR, the
product was cut with BspEI and XhoI, and introduced in
the pES31Hneo vector. The chimeric kappa light chain
was cloned in a pES33 vector in a similar way, using the
NM 101F, 14C5 VL B SOE, PH1 CL F SOE, and NM 264
B primers. SOE PCR was followed by a BspEI and XhoI
digest and introduced in the vector. The Fd fragment was
further extended to a complete Ab heavy chain by SOE
PCR extension with primers PH1 CH1 F SOE, CH1 Hi B,
CH2 F, CH2 B, CH3 F, and CH3 B, using pBRhIG1 as
template for the hinge, CH2, and CH3 regions. After
digestion with AgeI and BamHI enzymes, the product was
ligated in the pES33 vector. The heavy chain of the chF
(ab')2 fragment was amplified by PCR based on the heavy-
chain plasmid of the chAb by using NM 101F and the
human hinge BSpEI B primer. This fragment was cut with
XhoI and BspEI enzymes and ligated in the XhoI/BspEI-
digested plasmid containing VH of Ab 14C5 and CH1
region of PH1. A variant of the ch(Fab')2 was made with
the His-tag on the light chain instead of on the heavy
chain. This was done by exchanging the gene fragments 30
of the BspEI between the heavy- and light-chain expres-
sion plasmids using a BspEI/PvuI digest.
Production and derivatization
Light- and heavy-chain expression plasmids were tran-
siently cotransfected in HEK293T cells by the Ca3(PO4)2
precipitation method [25,26]. Enzymatic digestion of chAb
into chF(ab')2 and chFab was performed using the Pierce
W
F(ab')2 and Fab Preparation Kit (Thermo Scientific,
Erembodegem, Belgium) according to the manufacturer's
instructions.
Protein purification
Purification of the chFab 14C5 and the chF(ab')2 fragment
was performed by cation-exchange chromatography and
Dumolyn et al. EJNMMI Research 2013, 3:25 Page 3 of 10
http://www.ejnmmires.com/content/3/1/25Ni2+ affinity chromatography as described before [26].
The chFab and chF(ab')2 were concentrated and desalted
using Centricon centrifugal filter devices (Millipore,
Brussels, Belgium) with a cutoff of 30 and 50 kDa, respect-
ively. Purification of chAb 14C5 was performed on a pro-
tein A column (GE Healthcare, Diegem, Belgium) using
20 mM sodium phosphate running buffer (pH 7) and 0.1
M glycine (pH 2.7, Sigma-Aldrich, Bornem, Belgium)
elution buffer. Eluted fractions were neutralized immedi-
ately with 0.1 M Tris (pH 9, 100 μl/ml elution buffer).
Further purification was performed by size exclusion
chromatography on a Superdex-200 column (Amersham,
Bioscience, Uppsala, Sweden). All purification steps were
performed at 4°C on an Akta purifier system (Amersham
Bioscience, Uppsala, Sweden).
Analysis of protein fractions and stability determination
Primary antibodies used for detection of the Ab on West-
ern blot and in enzyme-linked immunosorbent assay
(ELISA) experiments were mouse anti-human kappa Ab or
mouse anti-his Ab (Sigma-Aldrich, Bornem, Belgium).
Alkaline phosphatase-conjugated anti-mouse IgG1 Ab
(Becton Dickinson-Pharmingen Biosciences, Erembodegem,
Belgium) was used as secondary Ab with the NBT/BCIP kit
(Invitrogen, Life Technologies, Merelbeke, Belgium) for
Western blot detection and p-nitrophenyl phosphate
(Sigma-Aldrich, Bornem, Belgium) for the detection in the
ELISA. Protein purity was analyzed by instant Coomassie
brilliant blue dye (Expedeon, Cambridgeshire, UK), and
specific detection of proteins was performed by immuno-
detection on a nitrocellulose membrane after Western blot-
ting. Protein concentration was determined with the Micro
BCA Protein Assay Kit (Pierce, Rockford, IL, USA) accor-
ding to the manufacturer's instructions. All constructs were
stored in different conditions (in phosphate-buffered saline
(PBS), in cell medium at 37°C and 4°C, and in mouse serum
at 37°C). Stability of the constructs was evaluated by SDS-
PAGE followed by Coomassie staining and Western blot
detection.
Cellular ELISA
A549 and Colo16 cells (104 cells/well) were coated in a
96-well plate and maintained at 37°C and 5% CO2 until
confluence. Cells were gently washed with 300 μl PBS
(Lonza, Verviers, Belgium). After fixation of cells with
100 μl PBS/acetone (2:3 (v/v), Sigma-Aldrich, Bornem,
Belgium), cells were washed again. The wells were
blocked with 2% PBS-M (2 g non-fat dry milk powder
(Nestlé, Brussels, Belgium)/100 ml PBS) for 1.5 h. A ½
sample dilution series was prepared in PBS-M and
added to the cells in triplicate. After 1.5 h of incubation
at 37°C, the cells were washed three times and incubated
with the primary detection Ab for 1 h at 37°C, washed
again for three times, and incubated with the secondarydetection Ab for 1 h at 37°C and washed again. Finally, the
cells were washed a last time with substrate buffer (1 mM
MgCl2 + 50 mM Tris (pH 9.5)), and detection was com-
pleted by adding detection buffer (1 tablet p-nitrophenyl
phosphate (Sigma-Aldrich, Bornem, Belgium)/5 ml sub-
strate buffer). Light absorbance at 405 nm was measured
after approximately 2 h at 37°C in a microplate reader
(Bio-Rad, Eke, Belgium).
Radioactive labeling and radiochemical stability
14C5 chAb and its derivatives were labeled with 125I or 131I
(PerkinElmer, Zaventem, Belgium) by incubating 10 min at
room temperature using the Iodo-Gen method [27].
Separation of protein-bound iodine from free iodine was
accomplished by purification over a PD10 column (GE
Healthcare, Diegem, Belgium). Radiochemical stability of
the iodinated molecules was assessed by instant thin
layer chromatography (iTLC; SG strips, Pall Corporation,
Zaventem, Belgium), by analysis of phosphorescence
image after SDS-PAGE, and by size-exclusion high-
performance liquid chromatography (HPLC) using a
Shodex KW 802.5 with a KW-G guard column (Thomson
Instrument Company, Oceanside, CA, USA). iTLC was
performed using 20 mM citric acid (pH 5.0, Sigma-
Aldrich, Bornem, Belgium) as eluent, strips were divided
into six parts, and radioactivity was counted with a NaI(Tl)
scintillation detector (PerkinElmer, Zaventem, Belgium).
The labeled compounds were incubated in medium (4°C
and 37°C), in PBS (4°C and 37°C), and in mouse serum
(37°C) and were analyzed for radiochemical purity after
several time periods.
Saturation binding assay
A dilution series of the labeled Ab and fragments was
added to 0.5 × 106 cells and incubated for 2 h at 4°C.
After centrifugation (15 s, 5,000×g) and washing with
ice-cold PBS (three times), the cell pellet was counted
for radioactivity using a gamma counter (Cobra II,
PerkinElmer, Zaventem, Belgium). The dissociation
constants (KD) were estimated (GraphPad Prism Soft-
ware 5.0, San Diego, CA, USA) to determine the binding
capacity of the Ab and fragments. The non-specific
binding curve was obtained in two different ways: by
incubation of the labeled molecule with the negative
control cell line Colo16 and by incubation in the pres-
ence of unlabeled mAb 14C5 with the antigen-positive
cell line A549.
Biodistribution
Nu/Nu athymic mice of 5 to 9 weeks old (Charles River,
L'Arbresle, France) were subcutaneously inoculated with
106 tumor cells into the flank. When tumors reached a
size of 0.5 to 1.0 g, biodistribution studies were per-
formed. Mice were injected in a tail vein with 5 μg of
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negative control chAb MabThera (kind gift of Ghent
University Hospital, Ghent, Belgium). Groups of four to
five mice were sacrificed 0.02, 1, 3, 6, 8, 10, 24, 48, 72,
and 168 h after injection. Tumor and organs were
removed, washed in PBS, blotted dry, and weighed.
Radioactivity in tumor, organs, and blood was detected with
a NaI(Tl) scintillation detector (PerkinElmer, Zaventem,
Belgium). Blood clearance studies were performed in 5- to
9-week-old Naval Medical Research Institute (NMRI) mice
(n = 3) (Charles River, L'Arbresle, France). Data were
analyzed by a two-phase exponential curve fit (GraphPad
Prism 5.0). All animal experiments were approved by
the Animal Experimental Ethical Committee of Ghent Uni-
versity Hospital (ECD 09/09). A non-parametric Mann–
Whitney U test was used for statistical comparison.
Results
Construction and production of 14C5 chAb and derivatives
Chimeric mAb 14C5 derivatives were generated by
recombinantly removing the 14C5 variable domains
from the mouse antibody and fusing them to the con-
stant domains of human IgG1. A full-size ch IgG1 was
made by fusing the 14C5 VH domain gene to the CH1
domain of a human IgG1 heavy-chain gene. Similarly,
the 14C5 VL domain gene was attached to the CL of a
human IgG1 light-chain gene. Both 14C5 gene con-
structs were integrated into the pES33 mammalian
expression vector and were co-expressed in the mamma-
lian HEK293T cell line. The cell supernatant containingFigure 1 Purification of chAb and chF(ab')2 14C5 produced by transfe
elution of chAb 14C5 (arrow indicates the chAb 14C5) (b), cation-exchange
(ab')2 (d). OD, optical density.the 14C5 chAb could be purified to a high degree by af-
finity purification on a protein A column, followed by
polishing on a size-exclusion column (Figure 1a,b).
Western blot analysis and Coomassie staining demon-
strated that the 14C5 chAb was correctly produced and
remained stable (Figure 2a,b, lane 2). Chimeric F(ab')2
and Fab fragments could then be successfully generated
by pepsin and papain enzymatic digestion, respectively
(Figure 2a,b, lanes 3 and 4). In order to simplify the
production of these derivatives, a recombinant construct
for 14C5 ch (Fab')2 was generated by removing the CH2
and CH3 domain genes from the heavy-chain construct.
Also, removing the hinge-region gene from the heavy-
chain vector led to a construct for a chFab 14C5. To
facilitate purification, a C-terminal E-tag or His6-tag was
added to the genes. After co-expressing the respective
heavy- and light-chain vectors in HEK293T cells, the
chAb derivatives were purified by cation-exchange chro-
matography followed by His-tag affinity purification
(Figure 1c,d). However, Coomassie staining and Western
blot analysis revealed that the majority of the chF(ab')2
was present in the form of dissociated F(ab') fragments
(Figure 2a,b, lane 5). In an attempt to aid the formation
of disulfide bridges, the F(ab') fragments were incubated
with increasing concentrations of oxidized glutathione.
However, this did not result in the formation of
functional F(ab')2 dimers. Additionally, removing the
His6-tag from the heavy chain did not result in improved
dimerization of F(ab') fragments. In contrast, the pro-
teolytically obtained chF(ab')2 (approximately 110 kDa,cted HEKT293T cells. Protein A elution of chAb 14C5 (a), gel filtration
chromatography elution of chF(ab')2 (c) and Hi-Trap elution of chF
Figure 2 SDS-PAGE analysis of the produced chimeric antibody and fragments 14C5. Visualized using Coomassie brilliant blue dye (a) and
specific visualization by Western blotting detected by mouse anti-human kappa antibody (lanes 2, 4, 5, and 6), mouse anti-His antibody (lane 3),
followed by anti-mouse IgG1 alkaline phosphatase (b): lane 1, protein marker; lane 2, ch antibody; lane 3, enzymatically produced chF(ab')2; lane
4, enzymatically produced chFab; lane 5, recombinant chF(ab')2; lane 6, recombinant chFab (a, b). Phosphorescence image after SDS-PAGE: lane 1,
estimated protein ladder based on non-radioactive protein marker; lane 2, 125I-ch antibody; lane 3, 125I-chFab; lane 4, 125I-chF(ab')2 14C5 (c).
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binantly produced chFab 14C5 fragment (approximately
50 kDa, Figure 2a,b, lanes 4 and 6) remained stable.
Further in vitro and in vivo experiments with 14C5 chAb
derivatives were performed with recombinantly pro-
duced chFab and proteolytically obtained chF(ab')2.Cellular ELISA
The affinity of the chAb derivatives was determined
through cellular ELISA on the αvβ5-expressing A549 cell
line. The αvβ5
− Colo16 cell line served as a negative control.
The KD for the 14C5 chAb and its fragments were deter-
mined from the fitted specific binding curves (Figure 3).
Due to their bivalent nature, 14C5 chF(ab')2 and chAb
(KD = 0.6 ± 0.05 nM and KD = 1.4 ± 0.11 nM, respectively)
showed a tenfold increase in relative affinity in comparison
to the monovalent chFab 14C5 (KD = 11 ± 2.34 nM).Figure 3 Saturation binding experiment of the chF(ab')2
(triangle), ch antibody (square), and chFab (circle) 14C5. By
cellular ELISA on A549 cells with mouse anti-human kappa antibody
(IgG1) and anti-mouse IgG1-alkaline phosphatase. Data are
expressed as mean ± SD (n = 3).Radioactive labeling and radiochemical stability
Radioiodination of the chAb and fragments resulted in a
typical yield between 75% and 85%. All labeled com-
pounds showed a radiochemical purity of more than
95% as verified by iTLC and HPLC. No free iodine was
present after HPLC and phosphorescence imaging after
SDS-PAGE. No aggregation or degradation of 125I-labeled
chAb 14C5 was observed (approximately 150 kDa,
Figure 2c, lane 2). The 125I-chFab (approximately 50 kDa,
Figure 2c, lane 3) and 125I-chF(ab')2 (approximately 110
kDa, Figure 2c, lane 4) revealed a low incidence of aggre-
gation (>180 kDa) and degradation (approximately 37
kDa), accounting for less than 5% of the total sample
radioactivity. All labeled constructs remained stable in
several conditions (in PBS, medium, and mouse serum, at
4°C and 37°C) over a longer period with a radiochemical
purity of more than 78% over a period of 3 days.Saturation binding assay
The affinity of the three 125I-radiolabeled 14C5 chAb de-
rivatives was compared in a saturation binding assay on
A549 cells (Figure 4). The KD was determined at 1.19 ±
0.19 nM for the 125I-labeled chAb, 0.27 ± 0.05 nM for
the parent murine Ab, 0.68 ± 0.10 nM for the chF(ab')2,
and 2.11 ± 0.58 nM for the chFab. The non-specific
binding curve obtained with the negative control Colo16
cells was similar to the non-specific curve obtained with
unlabeled mAb 14C5 incubated on αvβ5
+ A549 cells.
Biodistribution
In order to determine the pharmacokinetic properties of
the 14C5 chAb and its derivatives, blood clearance and
biodistribution studies were performed. The blood clear-
ance for all molecules was determined after injection of 5
to 10 μg of 131I-labeled product in NMRI mice (Figure 5a).
The estimated t1/2α was 19.6, 42.2, and 68.1 min for
131I-
Figure 4 Saturation binding assay of iodinated derivatives of the mAb 14C5 to A549 tumor cells. Specific (circle) and non-specific binding
(triangle) (binding to negative control Colo16 cell line) of 125I-chAb 14C5 (a), of 125I murine Ab 14C5 (b), of 125I-chF(ab')2 14C5 (c), and of
125I-chFab
14C5 (d). Data are expressed as mean ± SD (n = 3).
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more, the t1/2β values for chFab, chF(ab')2, and chAb were
estimated at 575.9, 867.8, and 3305 min, respectively. Sub-
sequently, A549 tumor-bearing athymic mice were
injected with the 131I-labeled chAb and its derivatives to
determine the biodistribution (see Additional file 2).Figure 5 Blood clearance in NMRI mice and tumor uptake and tumor
of 131I-labeled chFab, chF(ab')2, and chAb 14C5 in NMRI mice (a). Tumor up
(ab')2, and chFab 14C5 in A549 lung tumor-bearing mice. Values are correc
(n = 3 to 5).Maximum tumor uptake was reached at 1 h post injection
(p.i.) (2.51 ± 0.46%ID/g) for 131I-chFab 14C5, at 8 h p.i.
(5.73 ± 1.62%ID/g) for 131I-chF(ab')2, and at 24 h (11.56 ±
3.88%ID/g) for 131I-chAb (Figures 5b and 6). Total
radiation towards the tumor was assessed by integration
of tumor uptake over time. This resulted in area under the-to-blood ratio in A549 lung tumor-bearing mice. Blood clearance
take (%ID/g) (b) and tumor-to-blood ratio (c) of 131I-labeled chAb, chF
ted for decay of the radionuclide. Data are expressed as mean ± SD
Figure 6 Organ uptake of 131I-chFab, 131I-chF(ab')2, and
131I-chAb 14C5. Organ uptake (%ID/g tissue) of 131I-chFab (a), 131I-chF(ab')2 (b), and
131I-chAb 14C5 (c) in A549 lung tumor-bearing mice. Values are corrected for decay of the radionuclide. Data are expressed as mean ± SD (n = 3 to 5).
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Taking the amount of labeled compound in blood into
account, the tumor-to-blood ratios (T/Bs) were calculated,
which is an important characteristic for radioimmuno-
diagnosis (RID). The highest T/B of 131I-chFab was 0.88
from 3 h till 24 h p.i. The 131I-chF(ab')2 showed the
highest T/B after 24 h till 72 h p.i. with a maximum of
2.79 ± 1.24 at 48 h p.i. The T/B of 131I-chAb ranged from
0.70 to 0.94 between 24 and 168 h p.i. (Figures 5c and 6).
Another crucial property in RID and radioimmunotherapy
(RIT) is the specificity of the tracer and the expression of
the antigen. Exposure of normal tissue to radiation needs
to be minimal to avoid non-specific damage. The highest
non-specific uptake in the kidneys was seen with the 131I-
chFab fragment 1 h p.i. The non-specific uptake of the
tracer after 24 h p.i. in the lung, stomach, spleen, liver, and
kidneys were markedly more elevated for the chAb 14C5
compared to its derivatives (Figure 6). Biodistribution of
131I-14C5 chAb in αvβ5
− Colo16 tumor-bearing mice
revealed a high initial uptake at 24 to 48 h p.i., which
decreased significantly at 72 h p.i. (p < 0.05, non-
parametric Mann–Whitney U test; Figure 7a). This is in
contrast to the uptake seen in A549 tumors which was
highest at 24 h p.i., remained high until 72 h p.i., and
decreased only at 168 h p.i. (Figure 7a). The T/Bs in the
Colo16 model also illustrate the diminished tumor reten-
tion as compared to the specific A549 tumor model
(Figure 7b). The maximum Colo16 tumor uptake was
11.32 ± 2.48%ID/g at 48 h p.i., and the T/Bs increased to 1
(Figure 7). Additionally, experiments with a labelednegative control chAb, 131I-MabThera, demonstrated a
significant lower uptake in the positive A549 tumor (max-
imum tumor uptake <5%ID/g) in comparison to the spe-
cific chAb 14C5 uptake A549 tumors (p < 0.05, non-
parametric Mann–Whitney U test; Figure 7).
Discussion
Chimeric Ab derivatives of the anti-αvβ5 mAb 14C5
were recombinantly produced to reduce the risk of
generating a HAMA response in humans. Chimerization
is the first major and the most reliable step towards a
more humanized therapeutic Ab molecule [28]. Comple-
mentarity-determining region grafting could decrease
immunogenicity further but often results in reduced
affinity or specificity for the target antigen. Safeguarding
the desired characteristics involves several labor-intensive
trial-and-error approaches [29,30]. Integrin αvβ5 expres-
sion is involved in several crucial steps of cancer prog-
ression such as cell adhesion, angiogenesis, and metastasis
[31,32]. Overexpression of αvβ5 has been demonstrated
not only on several tumor types, but also on non-
transformed tumor-promoting cells from the tumor
stroma, such as cancer-associated fibroblasts [33] and cells
from the neovasculature [11,14,34]. These accessory cells
are less likely to lose antigen expression, making αvβ5 a
very attractive target for Ab-based RID and/or RIT. The
murine mAb 14C5 was shown to hold great potential for
these applications, given the tenfold higher affinity for
αvβ5 of the 14C5 mAb (KD = 0.19 ± 0.07 nM) compared
to the commercially available murine P1F6 mAb
[13,14,17,35]. However, despite its promising characte-
ristics, the use of mAb 14C5 in humans might provoke a
Figure 7 Tumor uptake and tumor-to-blood ratio of 131I-labeled chAb 14C5 and 131I-labeled ch MabThera. Tumor uptake (%ID/g) (a) and
tumor-to-blood ratio (b) of 131I-labeled chAb 14C5 in A549 lung tumor-bearing mice and in Colo16-bearing mice and 131I-labeled ch MabThera in
A549 lung tumor-bearing mice. Values are corrected for decay of the radionuclide. Data are expressed as mean ± SD (n = 3 to 5). The asterisk
indicates p < 0.05, non-parametric Mann–Whitney U test.
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responses generally lead to a reduced therapeutic effect-
iveness and can lead to potentially life-threatening severe
allergic reactions. Replacing mouse Ab constant domains
with their human counterparts in chimeric constructs
generates less anti-chimeric Abs at lower titers as
compared to HAMA in patients given the parent murine
Ab [36]. A chimeric human IgG1 mAb 14C5 was recom-
binantly constructed, produced, and purified. After con-
firmation of its stability, the affinity of recombinantly
produced chAb 14C5 for the integrin αvβ5 was determined
by cellular ELISA assays and by saturation binding assays
with radioiodinated chAb. Both experiments revealed a
similar and high affinity of the chAb for its antigen (KD =
1.4 ± 0.11 nM and KD = 1.19 ± 0.19 nM, respectively).
Although the dissociation constant for the murine 14C5
mAb was ten times lower [13] compared to the chAb, this
still puts the chAb 14C5 on par with the P1F6 mAb. Blood
clearance studies of 131I-chAb 14C5 conducted in NMRI
mice revealed negligible differences in t1/2α and t1/2β in
comparison with the murine mAb 14C5 (t1/2α = 118 min
and t1/2β = 4067 min) [13], since human as well as mouse
IgG binds the mouse neonatal Fc receptor (FcRn) which
regulates serum half-lives of IgG in both species. However,
significantly different clearance values are expected in
human patients, since human FcRn binds to human but
not to mouse IgG, resulting in longer retention of the
chAb in the blood [37]. The highest tumor uptake for
chAb as well as for the murine mAb 14C5 [13,17] was
seen at 24 h p.i. of approximately 10%ID/g, which corre-
sponds to other high-affinity Abs, such as the humanized
anti-αvβ3 mAb Abegrin
™ (14%ID/g at 24 h p.i.) [38]. In
mice bearing the αvβ5
− Colo16 squamous tumor, an initial
high uptake of chAb 14C5 (approximately 10%ID/g at 24
and 48 h p.i.) was observed which decreased more rapidly
compared to the uptake in the αvβ5
+ A549 tumor. In
contrast, a negative control chAb MabThera showed
significant less uptake (<5%ID/g, p < 0.05) in the αvβ5
+A549 tumor in comparison with the uptake of chAb 14C5
in both αvβ5
+ and αvβ5
− tumor types. Additionally, staining
of different human tumor tissues with mAb 14C5 demon-
strated tumor cell membrane and/or tumor surrounding
stroma staining [14]. Tumor sections without tumor cell
membrane staining did reveal stroma staining which was
co-localized with a fibroblast-specific marker (data not
shown). Consequently, expression of integrin αvβ5 on
cancer-associated fibroblasts (CAFs) was confirmed. There-
fore, the uptake of chAb 14C5 seen in αvβ5
− Colo16-bearing
animals is attributed to binding on CAFs in the tumor
stroma and/or on neo-vasculature of the tumor. These
results confirm αvβ5 as a promising target for RID and RIT.
For RID smaller fragments with good tissue penetration
and a fast clearance are needed, while RIT requires a good
therapeutic index without too much collateral damage.
14C5 chAb Fab and F(ab')2 fragments were generated in
order to examine their pharmacokinetic properties and find
the best format for RID/RIT applications. Both the chFab
and chF(ab')2 obtained from proteolytic cleavage of the
chAb 14C5 as well as the recombinantly produced chFab
were correctly produced and remained stable. However,
expression of the chF(ab')2 vectors did not result in signifi-
cant amounts of correctly dimerized chF(ab')2. Analysis on
SDS-PAGE suggests that the stabilizing disulfide bridges
between chFab' fragments were not properly formed.
Procedures to oxidize the cysteine SH groups in order to
form chF(ab')2 or the removal of peptide tags on the heavy
chain did not result in increased yields of stable recombi-
nant chF(ab')2, leaving only the proteolytically obtained chF
(ab')2 for further experiments. In cellular ELISA, the avidity
of the bivalent 14C5 chF(ab')2 (KD = 0.6 ± 0.05 nM) for the
αvβ5
+ A549 lung tumor cell line was ten times higher com-
pared to the monovalent 14C5 chFab (KD = 11 ± 2.34 nM).
However, saturation binding experiments with 125I-labeled
compounds revealed a less pronounced difference between
the affinity of both fragments, with a KD = 0.68 ± 0.10 nM
and KD = 2.11 ± 0.58 nM for the
125I-chF(ab')2 and chFab
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14C5 murine F(ab')2 (KD = 0.37 ± 0.10 nM) and Fab (KD =
2.25 ± 0.44 nM) [17], indicating that the chimerization of
the fragments had no influence on the in vitro binding
characteristics. In vivo, for the chFab 14C5 fragment, the
peak tumor-to-blood ratio (0.9) was reached at 6 h p.i.
After 24 h the Fab was largely cleared from the system,
which makes it an interesting probe for RID, despite high
non-specific kidney uptake caused by renal clearance of
the small fragment (<60 kDa). Behr et al. [39] demon-
strated that administration of cationic amino acids, such
as D-lysine, reduced the renal uptake of small peptides.
The 131I-chF(ab')2 demonstrated improved tumor-to-blood
ratios compared to the Fab fragment, although the
molecule remained in circulation longer. The 131I-chF(ab')2
did however clear faster than the intact chAb. The AUC
value is an indication for the total amount of radiation in
the tumor. The chAb 14C5 AUC value (AUC[0 → 7d]
62.75%ID∙ d∙ g−1) was higher than the AUC value of its
fragments, suggesting a higher therapeutic efficacy. How-
ever, the long residence time of the intact Ab in the blood
may augment the risk of non-specific radiation damage
(e.g., bone marrow). Consequently, the faster clearing chF
(ab')2 might be an attractive alternative if dose-limiting
toxicity occurs after administration of the intact Ab. The
AUC values may be further improved by using radiometals
such as 111In and 90Y, which have been shown to improve
tumor retention times and AUC values of radiolabeled
immunologicals [40]. Internalization studies with 111In-
14C5 mAb have already demonstrated extended tumor
retention times compared to radioiodinated Ab 14C5 [35].Conclusions
In conclusion, this study demonstrated that chime-
rization of mAb 14C5 had little effect on the properties
of the mAb. The characteristics of the 14C5 chAb are
promising for RIT and monitoring, while the chF(ab')2
and chFab 14C5 have a high potential for RID of cancer.
In addition to these fragments, other Ab constructs
could be created with improved characteristics for both
RID and RIT. Smaller constructs, such as diabodies and
nanobodies for example, provide high penetration into
the tumor and a rapid blood clearance, which is highly
advantageous for RID. Larger constructs, such as mini-
bodies for example, provide longer target retention and
could be used in RIT [41].Additional files
Additional file 1: Primers used in the construction of chimeric
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bearing an A549 tumor.
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